Pediatric glioma histone H3.3 K27M/G34R mutations drive abnormalities in PML nuclear bodies

作者：Hsiao P. J. Voon, Linda L. Hii, Andrew Garvie, Maheshi Udugama, Brian Krug, Caterina Russo, Anderly C. Chüeh, Roger J. Daly, Alison E. Morey, Toby D. M. Bell, Stephen J. Turner, Joseph Rosenbluh, Paul M Daniel, Ron Firestein, Jeffrey R. Mann, Philippe Collas, Nada Jabado, Lee H. Wong · 发表于：Genome biology · 年份：2023 · DOI：10.1186/s13059-023-03122-5 · 被引用次数：20 · 研究领域：Retinoids in leukemia and cellular processes、Glioma Diagnosis and Treatment、Acute Myeloid Leukemia Research

BACKGROUND: Point mutations in histone variant H3.3 (H3.3K27M, H3.3G34R) and the H3.3-specific ATRX/DAXX chaperone complex are frequent events in pediatric gliomas. These H3.3 point mutations affect many chromatin modifications but the exact oncogenic mechanisms are currently unclear. Histone H3.3 is known to localize to nuclear compartments known as promyelocytic leukemia (PML) nuclear bodies, which are frequently mutated and confirmed as oncogenic drivers in acute promyelocytic leukemia. RESULTS: We find that the pediatric glioma-associated H3.3 point mutations disrupt the formation of PML nuclear bodies and this prevents differentiation down glial lineages. Similar to leukemias driven by PML mutations, H3.3-mutated glioma cells are sensitive to drugs that target PML bodies. We also find that point mutations in IDH1/2-which are common events in adult gliomas and myeloid leukemias-also disrupt the formation of PML bodies. CONCLUSIONS: We identify PML as a contributor to oncogenesis in a subset of gliomas and show that targeting PML bodies is effective in treating these H3.3-mutated pediatric gliomas.